whereas successful isolation of the pathogen but inability to identify the organism at the species level might be considered as needs improvement, depending on the clinical importance of species identification.
In the early 1980s, it was determined that the evaluation system needed to be enhanced for some analytes. Assessment of submitted survey results through the use of fixed-limits criteria was introduced. Two situations were occurring that required attention. The ubiquitous ability to measure some analytes very accurately produced mean ±3 SD ranges that were so narrow that it was possible for a participant laboratory to report results outside that range and be evaluated as unacceptable, even though the reported results were within a medically useful and reasonably acceptable range. Conversely, for certain analytes, the mean ±3 SD range remained excessively broad and the laboratory population appeared to show no improvement in accuracy toward a level more attuned to medical needs. In both instances, the use of fixed-limits evaluation criteria consistent with medical decision-making and within the technical capabilities of the instrument/method systems being used was considered to be a more desirable way to assess performance and stimulate improvement. These evaluation mechanisms, with some exceptions for peer group problems and nonnumeric results, continue to be used today. Notably, the CAP has always been willing to make a decision to not grade a specific analyte in a specific survey sample when the situation warrants such action. Survey samples are not specimens from humans; they do not always behave like human specimens in all analytical situations. The manufacture and distribution of survey samples can result in unexpected vagaries that must be taken into account with any evaluation system. Throughout the history of CAP interlaboratory survey development, there has been a continuing recognition that any system for evaluating survey results
reported by laboratories should include medical usefulness criteria as a major consideration. In all cases, however, these and other European workers are using objective criteria to arrive at analytical goals. They might be looking at different populations, but they all have an objective, scientific philosophy.
I think this is the way to go. When we in the US talk about defining medical usefulness by asking the opinions of individual clinicians, or even groups of clinicians, we are not using scientific criteria to resolve our problem, because medicine is primarily a subjective art to achieve certain results in patients. And we will inevitably get widely varying, anecdotal advice that is bound to change as 
